Compare YieldMax MSTR Option Income Strategy ETF (MSTY) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax MSTR Option Income Strategy ETF vs TG Therapeutics Inc — how do they compare? YieldMax MSTR Option Income Strategy ETF trades at $13.56, while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: TG Therapeutics Inc is trading nearer its 52-week high, YieldMax MSTR Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| MSTY | TGTX | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $108.80 | $59.06 |
52-Week Low | $11.55 | $26.39 |
Market Cap | — | $8.26B |
Enterprise Value | — | $8.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTY trades at $13.12, up 2.34% today but remains in a bearish technical trend with significant price erosion over the past six months. The ETF generates weekly distributions but has experienced substantial capital depreciation, with a $10,000 investment in January 2026 declining to approximately $6,614 by July 2026. Technical indicators show bearish momentum with resistance at $14 and support at $12, while fundamental valuation metrics remain unavailable for analysis.
The outlook remains challenging as MSTY's covered-call strategy caps upside potential while exposing investors to full downside risk. Despite high distribution yields, the structural limitations and dependence on underlying MSTR volatility create significant investment risks. Investors face uncapped losses despite regular payouts, with media coverage highlighting concerns about the ETF's long-term sustainability.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About YieldMax MSTR Option Income Strategy ETF
MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on MSTY →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
